ClinicalTrials.gg
RecruitingNCT06382038SmaPEUpdated Sep 9, 2026

Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism

An interventional study of mobile venous thromboembolism application (mVTEA) in Venous Thromboembolism, Pulmonary Thromboembolisms and Digital Health, sponsored by Navy General Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Navy General Hospital, Beijing · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,972
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 62 studies in Venous Thromboembolism with a site in China — 21 open to participants now, 23 under way, 2 of them phase 3. Venous Thromboembolism · China.

Planned enrollment
7th of 33
2,972 · median 530
Started
2026
with 4 others
No phase
10 of 62
5 open now
Primary completion
2028-09
later than 20 of 22 live
Registered
48th of 62
by date
Lead sponsor
3 of 62
Navy General Hospital, Beijing

Among the 62 studies in Venous Thromboembolism with a site in China, this one is the 7th largest by planned enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 with no phase, reaches primary completion later than 20 of the 22 other live ones, and was the 48th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

21 of the 62 studies in Venous Thromboembolism with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Venous Thromboembolism with a site in China, or all of them as a file.
02

Study summary

Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.

This study aims to evaluate the effects of a smart technology-assisted, patient-centered mobile health application for pulmonary thromboembolism management (mPEA) on the long-term outcomes of patients with pulmonary thromboembolism (PTE). The findings are expected to inform clinical practice and provide an evidence base for the long-term management of patients with PTE.

03

Conditions studied

  • Venous Thromboembolism
  • Pulmonary Thromboembolisms
  • Digital Health

Keywords

  • Venous Thromboembolism
  • Pulmonary Thromboembolisms
  • Digital Health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inpatients aged ≥18 years;
  • PTE confirmed through imaging examinations, meeting at least one of the following criteria: a.Newly diagnosed PTE during the current hospitalization; b. Prior PTE with imaging evidence of residual thrombus.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Previous PTE combined with CTEPH;
  • Mental retardation or a combination of other serious illnesses that make them incapable of living on their own;
  • Inability to use smartphones, computer tablets and other smart devices;
  • Being pregnant or breastfeeding;
  • Have participated in similar trials or are undergoing other clinical trials.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
2,972 participants (estimated)

Study arms

  • Experimental
    mPEA Management Group

    Patients randomly assigned to the mPEA management group will be discharged with mPEA-assisted patient-centered PTE management.

    Other: mobile venous thromboembolism application (mVTEA)

  • No intervention
    Routine Management Group

    Patients randomly assigned to the routine management group will be given routine post-discharge management in accordance with local clinical practice.

Interventions

  • Othermobile venous thromboembolism application (mVTEA)

    mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends venous thromboembolism (VTE)-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.

06

What researchers measure

Primary outcomes

  1. VTE-related composite event

    The primary outcome was the occurrence of VTE-related composite event at 1-year follow-up, which was defined as a composite of recurrent VTE, newly diagnosed deep vein thrombosis (DVT), chronic thromboembolic pulmonary hypertension (CTEPH), major bleeding, VTE-related rehospitalization, and all-cause death.

    Time frame: At 1-year follow-up

Secondary outcomes

  1. VTE events

    VTE events will be documented at the 3, 6, 12, and 24-month follow-up after discharge. VTE events are categorized into two groups: recurrent VTE and newly diagnosed DVT. Recurrent VTE is defined as the appearance of new evidence of VTE after acute VTE has been treated in the acute phase (2 weeks) with significant clinical improvement in signs and symptoms. According to the time of VTE recurrence, it is further categorized into early VTE recurrence (within 3 months after the last VTE occurrence) and late VTE recurrence (more than 3 months after the last VTE occurrence). DVT that occurred for the first time after discharge during the study period is classified as newly diagnosed DVT.

    Time frame: At 3, 6, 12, and 24-month follow-up

  2. Chronic thromboembolic pulmonary hypertension (CTEPH)

    The diagnosis of CTEPH will be documented at the 3, 6, 12, and 24-month follow-up.

    Time frame: At 3, 6, 12, and 24-month follow-up

  3. Chronic thromboembolic pulmonary disease (CTEPD)

    The diagnosis of CTEPD will be documented at the 3, 6, 12, and 24-month follow-up after discharge.

    Time frame: At 3, 6, 12, and 24-month follow-up

  4. Post-pulmonary embolism syndrome (PPES)

    The diagnosis of PPES will be documented at the 3, 6, 12, and 24-month follow-up after discharge

    Time frame: At 3, 6, 12, and 24-month follow-up

  5. Major bleeding

    The major bleeding events as defined by the International Society on Thrombosis and Hemostasis (ISTH) will be documented at the 3, 6, 12, and 24-month follow-up after discharge.

    Time frame: At 3, 6, 12, and 24-month follow-up

  6. VTE-related hospitalization

    Rehospitalization due to VTE recurrence, progression, or complications related to VTE treatment will be documented during the follow-up.

    Time frame: At 3, 6, 12, and 24-month follow-up

  7. Death

    Death will be documented during the follow-up. It is categorized into all-cause death and PTE-related death. All-cause death is defined as death that occurs during the study period, regardless of cause. PTE-related death is defined as death that is unequivocally due to PTE.

    Time frame: At 3, 6, 12, and 24-month follow-up

  8. Patient-Reported Outcome Events (PROs)

    PROs will be documented during the 3, 6, 12, and 24-month follow-up after discharge. PROs refer to information directly conveyed by patients themselves concerning their health status, symptoms, functional capacity, or adverse events related to treatment, without the need for interpretation or mediation by clinicians or other third parties.

    Time frame: At 3, 6, 12, and 24-month follow-up

  9. Generic quality of life

    Generic, non-disease-specific health-related quality of life (QoL) is assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire and its corresponding visual analogue scale at 6, 12, and 24 months after discharge. Briefly, the EQ-5D-5L generates an overall index that ranges from 0 (lowest generic QoL) to 1 (highest generic QoL) and is calculated based on country-specific reference value sets. The EQ-5D-5L health index was calculated with the value set for China. The EuroQol visual analogue scale ranges from 0 to 100, with higher scores indicating better health.

    Time frame: At 6, 12, and 24-month follow-up

  10. Costs of management for healthcare staff

    Costs of healthcare staff training (training duration × hourly wage), including training on standardized management of pulmonary embolism and the use of mVTEA; costs associated with post-discharge patient management by healthcare personnel (such as follow-up management, rehabilitation management, health counseling, and comorbidity management), calculated as (consultation time/re-hospitalization time × hourly wage); and development costs for mobile technology and intelligent algorithms.

    Time frame: At 3, 6, and 12-month follow-up

  11. Treatment costs for VTE-related patients

    Treatment costs for VTE-related patients within 12 months post-discharge: These include registration fees, diagnostic costs, and treatment expenses incurred during visits to community clinics, hospital emergency departments, or specialist outpatient clinics due to changes in PTE condition (such as VTE recurrence, newly diagnosed DVT, bleeding, CTEPH, CTEPD, or PPES). They also encompass diagnostic and treatment expenses during hospital admissions in community or specialist settings due to changes in PTE condition. Additionally, costs arising from routine VTE follow-ups (without any changes in VTE-related conditions) at community clinics, hospital emergency departments, or specialist outpatient clinics are included.

    Time frame: At 1-year follow-up

  12. Treatment costs for non-VTE-related patients

    Treatment costs for non-VTE-related patients within 12 months post-discharge: These comprise registration fees, diagnostic costs, and treatment expenses associated with visits to community clinics, hospital emergency departments, or specialist outpatient clinics for non-VTE-related conditions, as well as diagnostic and treatment expenses during hospital admissions in community or specialist settings for non-VTE-related diseases.

    Time frame: At 3, 6, and 12-month follow-up

  13. Anticoagulant adherence

    Adherence would be assessed at months 3, 6, and 12 after discharge (defined as: the number of patients taking anticoagulants as prescribed/total number of patients at follow-up time point × 100%).

    Time frame: At 3, 6, and 12-month follow-up

  14. Probability of PTE progression

    Clinical cure rate of PTE (defined as the numbers of patients without VTE recurrence, newly diagnosed DVT, bleeding, CTEPH, CTEPD, PPES, or all-cause mortality / total number of patients at the follow-up time point × 100% ); VTE (PTE/DVT) recurrence rate; incidence rate of newly diagnosed DVT; bleeding incidence rate; major bleeding incidence rate; non-major bleeding incidence rate; CTEPH incidence rate; CTEPD incidence rate; PPES incidence rate; all-cause mortality rate; PTE-related mortality rate would be collected.

    Time frame: At 3, 6, and 12-month follow-up

  15. Effectiveness evaluation

    Quality-Adjusted Life Year(QALY) with EQ-5D-5L questionnaire would be investigated at 3, 6, and 12 months post-discharge and when the occurrence of VTE-related adverse events, including newly diagnosed DVT, bleeding, CTEPH, CTEPD, PPES, or all-cause mortality.

    Time frame: At 3, 6, and 12-month follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Valerio L, Mavromanoli AC, Barco S, Abele C, Becker D, Bruch L, Ewert R, Faehling M, Fistera D, Gerhardt F, Ghofrani HA, Grgic A, Grunig E, Halank M, Held M, Hobohm L, Hoeper MM, Klok FA, Lankeit M, Leuchte HH, Martin N, Mayer E, Meyer FJ, Neurohr C, Opitz C, Schmidt KH, Seyfarth HJ, Wachter R, Wilkens H, Wild PS, Konstantinides SV, Rosenkranz S; FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J. 2022 Sep 21;43(36):3387-3398. doi: 10.1093/eurheartj/ehac206. PubMed 35484821 ↗
  • Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010 Jan;8(1):202-4. doi: 10.1111/j.1538-7836.2009.03678.x. Epub 2009 Oct 30. PubMed 19878532 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2028, 25 months after the start.

Of 65 non-industry interventional studies with no phase under Venous Thromboembolism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 25 months is below that.

Counting every sponsor, half of 70 studies reached it within 31 months; a quarter within 19 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 24, 2024
StartActual
Aug 20, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2029
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06382038
Lead sponsor
Navy General Hospital, Beijing
Responsible party
Sponsor
First posted
Apr 24, 2024
Start date
Aug 20, 2026
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Sep 9, 2026

Study contacts

ZHI-GENG JIN, Doctor
Contact
lwgjzg@163.com
8615801402223
YU-TAO GUO, Doctor
study chair · Sixth Medical Center of Chinese PLA General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion